Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Status:
Not yet recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a single-center, prospective, single-arm, phase II clinical study, with the purpose
to evaluate the therapeutic efficacy and safety of envafolimab combined with
chemoradiotherapy and recombinant human endostatin in patients with locally advanced
nasopharyngeal carcinoma.